Induction of graft-versus-host disease and a graft-versus-leukemia effect using ubenimex in a patient with infantile leukemia relapsing after an unrelated cord blood transplant.
A 20-month-old boy with infantile leukemia was treated with total body irradiation, etoposide, cyclophosphamide and unrelated cord blood transplantation with a one-antigen mismatch. He relapsed on day 100 and achieved remission after ubenimex administration, and also developed chronic graft-versus-host disease of the skin. He remained in remission for 22 months with repeated courses of ubenimex. Ubenimex may be an alternative to donor lymphocyte transfusion and may be useful for the treatment of a patient who has relapsed after cord blood transplantation.
D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D006086:Graft vs Host Disease / Q000139:chemically induced*; D020544:Graft vs Leukemia Effect / Q000187:drug effects*; D006801:Humans; D007223:Infant; D007930:Leucine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D007938:Leukemia / Q000628:therapy*; D008297:Male; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D014184:Transplantation, Homologous
D007930:Leucine; C012211:ubenimex